ATE301722T1 - Integrin-zielvektoren mit transfektionaktivität - Google Patents

Integrin-zielvektoren mit transfektionaktivität

Info

Publication number
ATE301722T1
ATE301722T1 AT98924478T AT98924478T ATE301722T1 AT E301722 T1 ATE301722 T1 AT E301722T1 AT 98924478 T AT98924478 T AT 98924478T AT 98924478 T AT98924478 T AT 98924478T AT E301722 T1 ATE301722 T1 AT E301722T1
Authority
AT
Austria
Prior art keywords
transfection activity
target vectors
integrin target
integrin
nucleic acid
Prior art date
Application number
AT98924478T
Other languages
German (de)
English (en)
Inventor
Stephen Lewis Hart
Original Assignee
Ich Productions Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ich Productions Ltd filed Critical Ich Productions Ltd
Application granted granted Critical
Publication of ATE301722T1 publication Critical patent/ATE301722T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Electrotherapy Devices (AREA)
  • Compression Or Coding Systems Of Tv Signals (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT98924478T 1997-05-29 1998-05-29 Integrin-zielvektoren mit transfektionaktivität ATE301722T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711115.7A GB9711115D0 (en) 1997-05-29 1997-05-29 Integrin-targeting vectors having enhanced transfection activity
PCT/GB1998/001577 WO1998054347A1 (en) 1997-05-29 1998-05-29 Integrin-targeting vectors having transfection activity

Publications (1)

Publication Number Publication Date
ATE301722T1 true ATE301722T1 (de) 2005-08-15

Family

ID=10813246

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98924478T ATE301722T1 (de) 1997-05-29 1998-05-29 Integrin-zielvektoren mit transfektionaktivität

Country Status (9)

Country Link
US (2) US6458026B1 (https=)
EP (1) EP1003898B1 (https=)
JP (1) JP4293292B2 (https=)
AT (1) ATE301722T1 (https=)
AU (1) AU7667398A (https=)
CA (1) CA2288840A1 (https=)
DE (1) DE69831156T2 (https=)
GB (1) GB9711115D0 (https=)
WO (1) WO1998054347A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1230441C (zh) 2000-04-12 2005-12-07 安盛药业有限公司 结合整联蛋白的肽衍生物
AU2001258659A1 (en) * 2000-05-30 2001-12-11 Ich Productions Limited Improved methods of transfection
EP1178117A1 (en) * 2000-08-02 2002-02-06 Erasmus Universiteit Rotterdam Targeting through integrins
NO20004795D0 (no) 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
US8613907B2 (en) * 2000-10-12 2013-12-24 University Of Rochester Compositions that inhibit proliferation of cancer cells
GB0106315D0 (en) 2001-03-14 2001-05-02 Ich Productions Ltd Transfection complexes
CA2449054C (en) * 2001-05-30 2011-01-04 The Scripps Research Institute Integrin targeting liposome for nucleic acid delivery
WO2003006491A2 (en) 2001-07-10 2003-01-23 Amersham Health As Peptide-based compounds for targeting intergin receptors
US7598421B2 (en) 2002-05-08 2009-10-06 Ucl Biomedica Plc Materials for the delivery of biologically-active material to cells
GB0210538D0 (en) * 2002-05-08 2002-06-19 Univ London Lipids and gene delivery
WO2004096140A2 (en) * 2003-04-25 2004-11-11 The Penn State Research Foundation Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds
GB0313132D0 (en) * 2003-06-06 2003-07-09 Ich Productions Ltd Peptide ligands
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
EP1687017B1 (en) 2003-10-24 2013-03-06 Gencia Corporation Methods and compositions for delivering polynucleotides
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
AU2007211334A1 (en) * 2006-02-01 2007-08-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
US10034674B2 (en) * 2006-02-02 2018-07-31 Steven C Chudik Universal anterior cruciate ligament repair and reconstruction system
GB0610636D0 (en) * 2006-05-30 2006-07-05 Univ London Materials and complexes for the delivery of biologically-active material to cells
RU2010107199A (ru) * 2007-07-31 2011-09-10 Дзе Джонс Хопкинс Юниверсити (Us) Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии для неопластических или инфекционных нарушений
PT2252627T (pt) * 2008-01-24 2017-07-24 Esperance Pharmaceuticals Constructos de fusão de domínio lítico e métodos para produzir e utilizar os mesmos
US20110256055A1 (en) 2008-12-23 2011-10-20 Ge Healthcare Limited Application of 99mtc peptide-based compound as a bone marrow imaging agent
EP4710943A3 (en) 2015-08-28 2026-04-29 Molecular Transfer, Inc. Transfection complexes and methods of using the same
CN108779074A (zh) 2016-03-01 2018-11-09 分子传递有限公司 植物病毒移动蛋白和其使用方法
GB201604235D0 (en) 2016-03-11 2016-04-27 Ucl Business Plc Lipids and complexes for the delivery of biologically-active material to cells
GB201803419D0 (en) * 2018-03-02 2018-04-18 Ucl Business Plc Complex for the delivery of cas9 proteins guide RNA to cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
CA2204254C (en) 1994-11-17 2010-02-16 Stephen Lewis Hart Internalisation of dna, using conjugates of poly-l-lysine and an integrin receptor ligand
US5736392A (en) * 1995-06-07 1998-04-07 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US5908777A (en) 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery

Also Published As

Publication number Publication date
WO1998054347A1 (en) 1998-12-03
US20030013644A1 (en) 2003-01-16
DE69831156T2 (de) 2006-06-08
US6458026B1 (en) 2002-10-01
DE69831156D1 (de) 2005-09-15
AU7667398A (en) 1998-12-30
US20020042384A1 (en) 2002-04-11
JP4293292B2 (ja) 2009-07-08
CA2288840A1 (en) 1998-12-03
EP1003898A1 (en) 2000-05-31
GB9711115D0 (en) 1997-07-23
EP1003898B1 (en) 2005-08-10
JP2002502243A (ja) 2002-01-22

Similar Documents

Publication Publication Date Title
DE69831156D1 (de) Integrin-zielvektoren mit transfektionaktivität
CA2166931A1 (en) Electrostatic bonding type macromolecular micelle drug carrier and drug carried thereon
BR9612677A (pt) Sistemas complementares de vetores adenovírais e linhagens celulares
ZA971159B (en) Target cell-specific vectors for inserting genes into cells, pharmaceuticals comprising such vectors and their use.
EP1019028A4 (en) $ I PROTEIN (CHLAMYDIA), GENE SEQUENCE, AND USES THEREOF
DE69333766D1 (de) Herstellung von phytat-degradierenden enzymen in trichoderma
EP0892048A3 (en) XAF genes and polypeptides and their use for modulating apoptosis
CA2281206A1 (en) Geranyl diphosphate synthase genes
AU1165899A (en) Conjugates comprising two active agents
NZ510154A (en) A tumour antigen protein and gene therefor, tumour antigen peptides and derivatives thereof in medicaments and prophylactics
CA2014948A1 (en) Genes coding for a protein having human macif activity, expression vectors containing said genes, transformant cells and proteins having human macif activity
WO2001092542A8 (en) Integrin-targeting vectors having enhanced transfection activity
EP1022332A4 (en) BETA FRUCTOFURANOSIDASE AND GENE CODING FOR IT
ATE175866T1 (de) Direktziehendes haarfärbemittel
FI971377L (fi) Adenovirusperäisiä virusvektoreita, joissa on kaksi terapeuttista geeniä: itsemurha- ja immuunistimuloiva geeni
NZ334744A (en) Method for determining expression of aberrant forms of APC protein
AU1099697A (en) Novel xylanases, genes encoding them, and uses thereof
WO2001000799A8 (fr) Nouvelle proteine et son adn
WO1999027432A3 (en) System and method for integrating heterogeneous information
EP1041146A4 (en) TUMOR ANTIGEN PROTEIN, ITS GENE AND ITS USE
CA2222594A1 (en) System for distributed task execution
CA2475337A1 (en) Methods for cultivating cells and propagating viruses
AU4121997A (en) Method for sorting antifungal molecules acting on the glucanosyltransferase activity
Powell et al. Road kill on the Infobahn.
Lipman et al. Avanti and Anagram merge.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties